Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer

Севабертитиниб при прогрессирующем немелкоклеточном раке легкого с мутациями HER2
Nicolas Girard, Pasi Antero Janne, Boon Cher Goh, Daniel Shao-Weng Tan, Nicoletta M. Brega, Tae Min Kim, Arsela Prelaj, Lin Wu, Kōichi Goto, Dominik Rüttinger, Herbert Ho-Fung Loong, Jan C. Brase, Hye Ryun Kim, Xiaorong Dong, Tsung‐Ying Yang, Xiuning Le, Weichao Bao, Silvia Novello, Yuki Shinno, Shun Lu, Liyun Miao, Shun Lu, Rui Li, Lin Li, Yong Fang, Yuki Shinno, Gennaro Daniele, Gerrina Ruiter, Jun Zhao, Tine Descamps, Paolo Grassi, Weichao Bao
2025-10-17

HER2-mutant non-small-cell lung cancerSevabertinibobjective response rateprogression-free survivaltreatment-related diarrhea
BACKGROUND: gene mutations occur in 2 to 4% of patients with non-small-cell lung cancer (NSCLC). Sevabertinib is an oral, reversible tyrosine kinase inhibitor that has shown anti-HER2 activity in preclinical models. METHODS: -mutant NSCLC. Three cohorts were defined according to previous therapy: cohort D comprised previously treated patients who had not received HER2-targeted therapy; cohort E, patients who had previously received HER2-directed antibody-drug conjugates; and cohort F, patients who had not previously received treatment. The primary end point was an objective response, as assessed by blinded independent central review. Secondary end points were duration of response and progression-free survival. RESULTS: A total of 209 patients received sevabertinib (as of June 27, 2025, the data-cutoff date); the median duration of follow-up was 13.8 months in cohort D, 11.7 months in cohort E, and 9.9 months in cohort F. Among 81 patients in cohort D, an objective response was observed in 64% (95% confidence interval [CI], 53 to 75); the median duration of response was 9.2 months (95% CI, 6.3 to 13.5), and the median progression-free survival was 8.3 months (95% CI, 6.9 to 12.3). Among 55 patients in cohort E, an objective response was observed in 38% (95% CI, 25 to 52); the median duration of response was 8.5 months, and the median progression-free survival was 5.5 months. Among 73 patients in cohort F, an objective response was observed in 71% (95% CI, 59 to 81), and the median duration of response was 11.0 months; data on progression-free survival were immature. Grade 3 or higher drug-related adverse events occurred in 31% of the patients. The most common adverse event was diarrhea (in 84 to 91%), with diarrhea of grade 3 or higher occurring in 5 to 23%. Treatment was discontinued by 3% of the patients owing to drug-related adverse events. CONCLUSIONS: -mutant NSCLC. Diarrhea was the most common adverse event. (Funded by Bayer; SOHO-01 ClinicalTrials.gov number, NCT05099172.).
1
Grade ≥3 drug‑related adverse events occurred in 31% of patients; diarrhea was the most common adverse event (84–91%), with grade ≥3 diarrhea in 5–23%; 3% discontinued due to drug‑related adverse events.
2
In treatment‑naive patients (cohort F), sevabertinib produced a 71% objective response rate with median duration of response 11.0 months.
3
Median duration of response was 9.2 months and median progression‑free survival 8.3 months in cohort D; cohort E had median duration 8.5 months and PFS 5.5 months.
4
Objective response rate was 38% in patients previously treated with HER2-directed antibody–drug conjugates (cohort E).
5
Sevabertinib demonstrated objective responses in HER2-mutant NSCLC across cohorts: 64% in previously treated non‑HER2‑targeted patients (cohort D).

Sevabertinib treatment in patients with advanced HER2-mutant non–small-cell lung cancer

Efficacy and safety outcomes including objective response rate, duration of response, progression-free survival, and treatment-related adverse events of sevabertinib in HER2-mutant NSCLC patients

Publication Details
Publication Date
2025-10-17
Journal
Publisher
ISSN
Cited by
86
Access Type
Author Information
Authors
Nicolas Girard
Pasi Antero Janne
Boon Cher Goh
Daniel Shao-Weng Tan
Nicoletta M. Brega
Tae Min Kim
Arsela Prelaj
Lin Wu
Kōichi Goto
Dominik Rüttinger
Herbert Ho-Fung Loong
Jan C. Brase
Hye Ryun Kim
Xiaorong Dong
Tsung‐Ying Yang
Xiuning Le
Weichao Bao
Silvia Novello
Yuki Shinno
Shun Lu
Liyun Miao
Shun Lu
Rui Li
Lin Li
Yong Fang
Yuki Shinno
Gennaro Daniele
Gerrina Ruiter
Jun Zhao
Tine Descamps
Paolo Grassi
Weichao Bao
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%